Adefovir for lamivudine-resistant hepatitis B

Rebecca Roediger, Elizabeth Kula Smyth, Douglas Dieterich

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Adefovir, a nucleotide analog developed by John Martin, was a major breakthrough in the treatment of chronic Hepatitis B. Prior to adefovir, Hepatitis B treatment was limited to two therapeutic modalities, either interferon, which carried significant side effects and was efficacious in a minority of patients, or lamivudine which showed no durable effects with short-term use and a high rate of resistance with long-term use. Adefovir was found to be effective in suppressing viral replication and in resolving the hepatic inflammation associated with hepatitis B with only rare instances of resistance. In this article, we appreciate John Martin’s contribution to science and medicine as we review the landmark trials of adefovir that brought forth a new era of treatment of Hepatitis B.

Original languageEnglish
JournalAntiviral Therapy
Issue number1
StatePublished - 5 Feb 2022


Dive into the research topics of 'Adefovir for lamivudine-resistant hepatitis B'. Together they form a unique fingerprint.

Cite this